Finally, another three clinical trials are active to evaluate its efficacy in brain metastases from HER-2-positive breast tumors (NCT04420598) and in HER-2-positive breast tumors that cannot be surgically removed or that have spread (NCT03523585, NCT03529110) comparing its efficacy with conventional chemotherapy (capecitabine) plus an HER-2-targeted agent (lapatinib or trastuzumab). This evidence concerns the gene ERBB2 and breast neoplasm.